Recombinant Baculovirus Vaccine Vector for HPV Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HPV vaccine development faces challenges with viral vectors like retrovirus and adenovirus, which cause cytotoxicity, early immune responses, and expression of undesired genes, and baculovirus-based vaccines require improved immune response induction.
Innovation Solution
A recombinant baculovirus is developed by combining nucleotide sequences encoding antigen genes and foreign virus envelope proteins, specifically using a HERV envelope protein, to enhance immune responses and create a stable, economic vaccine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If retrovirus or adenovirus is used as viral vectors for HPV gene delivery, then gene transfer efficiency is improved, but cytotoxicity and early immune responses are induced
Solution Approach 1:
The patent extracts the harmful replication-dependent viral genes from the viral vector while retaining the beneficial gene delivery capability. By using a replication-deficient baculovirus vector, the harmful cytotoxicity and uncontrolled replication are removed, while the ability to deliver HPV genes remains intact through alternative mechanisms such as nuclear transfection and sustained gene expression.
Solution Approach 2:
The patent introduces an intermediary approach by using baculovirus as a non-replicating vector that mediates gene delivery through nuclear transfection rather than replication. This intermediary mechanism allows efficient gene transfer without triggering the harmful cytotoxicity and immune responses associated with replicating viruses like retrovirus and adenovirus.
2Reliability
If baculovirus is used as a vaccine vector, then biological safety is improved, but immune response induction is insufficient
Solution Approach 1:
The patent merges the safe baculovirus vector with enhanced immunogenic adjuvants and modified viral envelope proteins. This combination strategy maintains the biological safety of baculovirus while significantly enhancing immune response induction through synergistic effects of the adjuvants and viral components, achieving both safety and efficacy simultaneously.
Solution Approach 2:
The patent applies parameter changes by modifying the baculovirus vector characteristics such as envelope protein composition, antigen loading methods, and delivery parameters. These modifications optimize the balance between biological safety and immune response induction, enabling the vector to elicit strong protective immunity while maintaining its safe profile.
3Productivity
If conventional viral vectors are used for HPV vaccination, then immune response is induced, but undesired viral genes are expressed
Solution Approach 1:
The patent extracts and removes undesired viral genes from the vector genome, retaining only the beneficial HPV antigen coding sequences. By using a carefully designed baculovirus vector with specific gene inserts and eliminating replicating viral genes, the system induces immune responses without expressing harmful viral genes that would cause cytotoxicity or unwanted immune reactions.
Data Source
AI summary
The present invention relates to a recombinant baculovirus comprising: (a) a nucleotide sequence encoding a foreign virus envelope protein; (b) a first promoter operatively linked to the envelope-encoding nucleotide sequence; (c) a nucleotide sequence encoding an antigen protein; and (d) a second promoter operatively linked to the antigen-encoding nucleotide sequence; and a vaccine composition using the same. The recombinant baculovirus of the present invention has an excellent efficacy on both humoral and cellular immune responses against a specific antigen (e.g., HPV L1), enabling to function as a more efficient DNA vaccine.